UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 18, 2023
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware |
| 001-33357 |
| 65-0643773 |
(State or other jurisdiction | | (Commission File Number) | | (IRS Employer |
| | | | |
2 University Plaza | | | | |
Suite 100 | | | | |
Hackensack, NJ | | | | 07601 |
(Address of principal executive offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code 201-696-9345
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common stock, $0.001 par value | PLX | NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
Item 2.02Results of Operations and Financial Condition
On May 18, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release which, in part, disclosed the Company’s current cash and cash equivalent position. Such portions of the press release are furnished in Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the specified information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 8.01Other Events
The press release referenced in Item 2.02 included an announcement by the Company that it is eligible to receive a $20��million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group (Chiesi). The milestone payment was triggered by the approval by the U.S. Food and Drug Administration of ELFABRIO® (pegunigalsidase alfa-iwxj) for the treatment of adult patients with Fabry disease. Except as set forth in Item 2.02, a copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01Financial Statements and Exhibits
| |||
Exhibit No. |
| Description | |
99.1 | | ||
104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 18, 2023 | PROTALIX BIOTHERAPEUTICS, INC. | ||
|
|
|
|
| By: | /s/ Dror Bashan | |
|
| Name: | Dror Bashan |
|
| Title: | President and Chief Executive Officer |